An apparatus for determining blood clotting capacity comprises an actuator to cyclically move a member within a sample of blood received in a well in a tray and one of a deflection sensor and a position sensor to determine the position of the wetted member upon being acted upon by the actuator. The theoretical position of the wetted member, as determined using a known actuator force and wetted member physical data, is compared to the sensed deflection or position of the wetted member, and the resistance to movement of the wetted member caused by the blood is determined and correlated to a clotting capacity.

A sample testing cartridge is usable to perform a variety of tests on a visco-elastic sample, such hemostasis testing on a whole blood or blood component sample. The cartridge includes a sample processing portion that is in fluid communication with a sample retention structure. A suspension, such as a beam, arm, cantilever or similar structure supports or suspends the sample retention portion relative to the sample processing portion in a unitary structure. In this manner, the sample retention portion may be placed into dynamic excitation responsive to excitation of the cartridge and correspondingly dynamic, resonant excitation of the sample contained within the sample retention portion, while the sample processing portion remains fixed. Observation of the excited sample yields data indicative of hemostasis. The data may correspond to hemostasis parameters such as time to initial clot formation, rate of clot formation, maximum clot strength and degree of clot lysis.

Disclosed is a method for analyzing a blood specimen, including the steps of: coagulating a blood specimen in the presence of an activating agent for fibrinolytic system to acquire a coagulation waveform; and acquiring information about fibrinolytic capacity of the blood specimen based on the acquired coagulation waveform.

Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level. The determined platelet coagulability level of said blood sample is compared with a threshold level of blood platelet coagulability. A determined platelet coagulability level above said threshold level indicates that a risk of restenosis is relatively high. If the determined platelet coagulability level is below said threshold level, a bare metal stent is selected. If the determined platelet coagulability level is at or above said threshold level, a drug-eluting stent is selected.

There is disclosed an apparatus is disclosed for monitoring blood coagulation comprising a main body; a test chamber for receiving a fluid sample; and a rotor disposed within the test chamber. The rotor comprises a buoyancy chamber for reducing the apparent weight of the rotor when fluid is positioned within the test chamber.

A blood coagulation analyzer comprises: a light irradiation unit configured to apply light onto a container configured to store a measurement specimen containing a sample and a reagent, and comprising: light sources including a first light source configured to generate light of a first wavelength for blood coagulation time measurement, a second light source configured to generate light of a second wavelength for synthetic substrate measurement, and a third light source configured to generate light of a third wavelength for immunonephelometry measurement; and optical fiber parts facing the respective light sources; a light reception part configured to receive light transmitted through the container; and an analysis unit configured to analyze the sample using an electric signal outputted from the light reception part.

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

A method of operating a pump can include advancing a stepper motor one or more additional steps in a first direction after detecting a first change in a limit sensor state corresponding to a piston reaching an end of its travel in a first direction. After advancing the stepper motor the additional step or steps in the first direction, the stepper motor can be reversed and advanced in a second direction until a second change in the limit sensor state is detected. The stepper motor can then be advanced in the second direction a predetermined number of steps associated with a full travel of the piston.

The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the clots being formed.

The present invention relates to a method for dynamically determining the structural profile of a fibrin clot, reflecting the stability thereof in a biological sample of a patient. The method preferably includes a step that makes it possible to predict the risk of bleeding, thrombosis or rethrombosis and to select the anticoagulant that is best suited to the clinical situation of a patient.